Combined blocking of TGFβ -activated kinase 1 (TAK1) and TGFBR1 inhibits IL1β/TGFβ1-mediated fibroblast activation, reduces secretion of pro-inflammatory cytokines and makes tumor cells more sensitive to chemotherapy [295]. Here, TGFB1 is linked to neoplasm.